was successfully added to your cart.

Your SEO optimized title page contents

Mayes Discusses Health Canada and MMJ Requirements on BBN

mmj requirements

Health Canada and MMJ Requirements

MMJ requirements for the medical marijuana industry are incredibly complex and cumbersome as Health Canada takes a hard look at companies that are looking to win production licenses. Michael Mayes, CEO at consulting firm Quantum 9, appeared on BNN for an inside look at what potential producers must go through.

Here are a few points that Mayes discussed on the show:

  • Quantum 9 works primarily in North America, but also France and Holland. We do permanent acquisition consulting primarily around quality assurance, security, keeping good manufacturing processes and SOP’s. We help create a path that guides venture capitalists and entrepreneurs looking to acquire licenses from Health Canada.
  • Health Canada is doing their due diligence and it has caused a bit of a slowdown in the regulatory process. Rigorous analysis is being done on the quality assurance side of businesses to ensure that the quality of medicine that patients will be receiving is top-notch.
  • Facilities are required to have an industrial-sized bank vault and caging requirements for curing cannabis to deter theft into the black market.
  • Canada’s MMPR program is unique in that it allows an e-commerce model. As a result, the world is looking to Canada as an innovator in the way the address and license producers, as well as the way product being disseminated.
  • The financial requirements for capital and pursuit capital are quite high. It doesn’t mean you necessarily have to build an entire facility prior to getting a license, but it will require tremendous capital.
  • We do a tremendous amount of cultivation design. Typically, our cultivation staff go through a locker room in which they’ll change out of their street clothes, they’ll shower and then dress in pocketless gowns. So before entering a propagation area, they’ve completely removed any impurities from the outside. There’s a lot of things in the facility that can be designed to prevent from pest and pathogens.
  • As far as the potential for pharmaceutical companies to take over the industry, Mayes points out that capital is king in any industry, and if a pharmaceutical company has those types of resources, there would be no barrier of entry.

About Michael Mayes

As Chief Executive Officer for Quantum 9, Inc., Michael has assisted in funding some of the largest commercial cannabis projects in the world. Michael has been a cannabis investor since 2009 in Colorado’s first legal for-profit cannabis market. As the co-founder and CEO of Quantum 9, Inc., Michael has spent years designing technology and collaborating with countless consultants on the forefront of the cannabis industry. Collaborating with the brightest minds and contributing to world-class organizations has been an incredibly enlightening and rewarding experience for him. Also, he has amassed a comprehensive and award-winning team engaged globally for public policy best practices through the prioritization of environmental sustainability and patient care. Michael is a member of the International Cannabinoid Research Society (ICRS), contributor to Marijuana Business Daily, quoted in the Chicago Tribune, Tampa Tribune, Yahoo Finance, Tampa Tribune, Sativa Magazine, CBC and the Daily Herald. His media appearances include several CBS and WGN appearances and international presence on BNN Commodities in Canada. On the public policy front, Michael and his team were instrumental in their work of drafting the Kentucky Medical Marijuana Bill for Senator Perry Clark. Most recently, Michael taught a class for the International Pharmaceutical Academy in Toronto, Canada. He spoke on Cannabis Pharmacology, and the effects cannabis has on the endocannabinoid system.

Leave a Reply